Watch ELTX. Know when insiders buy.
One email the day a filing lands. Free.
ELTX
Elicio Therapeutics, Inc.
2.05
−0.06 −2.84%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
60
WATCH · shorts 60
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $53.9MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$37.8MNET CASH $13.5M52W 2.05 – 14.85SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$10.4M | −$8.2M | — | -0.43 | −$8.2M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$10.6M | −$11.8M | — | -0.65 | −$11.6M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$8.8M | −$7.7M | — | -0.49 | −$6.8M | $16K | −$6.8M | Mar 12 |
| Q3 2025 · Sep 30 | — | — | — | −$8M | −$10.1M | — | -0.60 | −$11.1M | $0 | −$11.1M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$10.1M | −$10.6M | — | -0.66 | −$8.9M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$10.7M | −$11.2M | — | -0.87 | −$10.1M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$13.5M | −$14M | — | -1.02 | −$8.7M | $45K | −$8.8M | Mar 12 |
| Q3 2024 · Sep 30 | — | — | — | −$10.3M | −$18.8M | — | -1.39 | −$7.3M | $0 | −$7.3M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$10.9M | −$7.2M | — | -0.64 | −$8.9M | $42K | −$9M | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$10.2M | −$11.8M | — | -1.15 | −$12.1M | $0 | −$12.1M | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$9.4M | −$8.9M | — | -0.21 | −$9.9M | $0 | −$9.9M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$10.8M | −$10.7M | — | -1.27 | −$5.2M | $45K | −$5.2M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$37.7M | −$39.6M | — | -2.58 | −$37M | $16K | −$37M | — | — |
| FY2024 · to Dec 31 | — | — | −$45M | −$51.9M | — | -4.25 | −$37.1M | $87K | −$37.2M | — | — |
| FY2023 · to Dec 31 | — | — | −$35.7M | −$35.2M | — | -6.96 | −$32.7M | $66K | −$32.8M | — | — |
| FY2022 · to Dec 31 | $2.3M | 100.0% | −$23.7M | −$28.2M | -1225.9% | -89.27 | −$22.2M | $654K | −$22.8M | — | — |
| FY2021 · to Dec 31 | $28.3M | 98.5% | −$39.3M | −$54.6M | -192.8% | -1.93 | −$52.6M | $382K | −$53M | — | — |
| FY2020 · to Dec 31 | $2.9M | 58.7% | −$55.3M | −$80.1M | -2781.5% | -5.43 | −$22.9M | $41K | −$22.9M | — | — |
Every number comes from Elicio Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.